Sumitomo Pharma Co. Ltd. is a Japanese pharmaceutical company founded in 1897 and headquartered in Osaka, Japan, focusing on the research, development, and manufacturing of innovative pharmaceutical products. The company's portfolio includes a range of therapeutic areas such as psychiatry, neurology, and oncology, with notable products like the antipsychotic agent Latuda and the anti-cancer drug Sumitomo Dainippon Pharma's Epclusa.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| DAINIP 1.39% 2050-09-09 JPYSumitomo Pharma Co. Ltd. | Japan | 2050-09-09 | 1.390 | 5.45 |
| DAINIP 1.55% 2050-09-09 JPYSumitomo Pharma Co. Ltd. | Japan | 2050-09-09 | 1.550 | 7.71 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Sumitomo Pharma began issuing bonds in the early 2000s, with significant issuances aimed at financing research and development initiatives. In 2019, the company issued ¥30 billion of green bonds, showcasing its commitment to sustainability in healthcare. Currently, the yields on Sumitomo Pharma's bonds are competitive within the industry, reflecting strong creditworthiness and investor confidence. Recent financial news highlights the company’s plans for further bond issuances to support expansion in global markets, which could offer unique investment opportunities.